Performance qualification of a new hypromellose capsule: Part I. Comparative evaluation of physical, mechanical and processability quality attributes of Vcaps Plus®, Quali-V® and gelatin capsules

International Journal of Pharmaceutics

Volumn 386, Issue 1-2, 2010, Pages 30-41

  Sherry Ku, M ^a   Li, Weiyi ^a   Dulin, Wendy ^a   Donahue, Fran ^a   Cade, Dominique ^b   Benameur, Hassan ^b   Hutchison, Keith ^b  

^a WYETH RESEARCH   (United States)

^b PFIZER INC   (United States)

Author keywords

Compatability; Hypromellose capsule; In vivo performance; Machineability; Mechanical properties; Physical stability

Indexed keywords

CARRAGEENAN; EXCIPIENT; FORMALDEHYDE; GELATIN; HYDROXYPROPYLMETHYLCELLULOSE; PARACETAMOL;

ANIMAL EXPERIMENT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CROSS LINKING; DOG; DRUG CAPSULE; DRUG FORMULATION; DRUG SOLUBILITY; HIGH TEMPERATURE; HUMAN; MALE; NONHUMAN; POWDER; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; WETTABILITY;

ADMINISTRATION, ORAL; ANIMALS; CAPSULES; CARRAGEENAN; CHEMISTRY, PHARMACEUTICAL; CROSS-LINKING REAGENTS; CROSS-OVER STUDIES; DOGS; DRUG COMPOUNDING; DRUGS, INVESTIGATIONAL; EXCIPIENTS; FORMALDEHYDE; GELATIN; HARDNESS; HUMANS; MALE; METHYLCELLULOSE; POWDERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SOLUBILITY; STRESS, MECHANICAL; SURFACE PROPERTIES; TECHNOLOGY, PHARMACEUTICAL; TEMPERATURE; WETTABILITY;

EID: 74249099723     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2009.10.050     Document Type: Article

References (35)

1. Brown J., Madit N., Cole E.T., Wilding I.R., and Cade D. Effect of cross-linking on the in vivo disintegration of hard gelatin capsules. Pharm. Res. 15 (1998) 1026-1030
2. Cadé D., and Madit N. Liquid filling in hard capsules-preliminary steps. Bulletin Technique Gattefossé (1996) 15-20
3. Cade, D., Scott, R., He, X., 2003. Polymer film compositions for capsules. US Patent No. 6,517,865 B2, February.
4. ® Plus Two-Piece Capsules, Version 1.2.
5. Capsugel, 2009. Coni-Snap Capsules (Link: http://www.capsugel.com/products/conisnap_chart.php).
6. Chafetz L., Hong W.H., Tsilifonis D.C., Taylor A.K., and Philip J. Decrease in the rate of capsule dissolution due to formaldehyde from polysorbate 80 auto oxidation. J. Pharm. Sci. 73 (1984) 1186-1187
7. Cole E.T., Scott R.A., Cade D., Connor A.L., and Wilding I.R. In vitro and in vivo pharmacoscintigraphic evaluation of ibuprofen hypromellose and gelatin capsules. Pharm. Res. 21 (2004) 793-798
8. Cole S.K., Story M.J., Attwood D., Laudanski T., Robertson J., and Barnwell S.G. Studies using a non-ionic surfactant-containing drug delivery system designed for hard gelatin capsule compatibility. Int. J. Pharm. 88 (1992) 211-220
9. Digenis G.A., Gold T.B., and Shah V.P. Cross-linking of gelatin capsules and its relevant to their in-vivo performance. J. Pharm. Sci. 83 (1994) 915-921
10. Digenis G.A., Sandefer E.P., Page R.C., Doll W.J., Gold T.B., and Darwazeh N.B. Bioequivalence study of stressed and nonstressed hard gelatin capsules using amoxicillin as a drug marker and gamma scintigraphy to confirm time and GI location of in vivo capsule rupture. Pharm. Res. 17 (2000) 572-582
11. Doelker E., and Vial-Bernasconi A.C. Interactions contenant-contenu au sein des capsules gélatineuses et évaluation critique de leurs effets sur la biodisponibilité des principes actifs S.T.P Pharma vol. 4 (1988) 298-306
12. FDA BSE Testimony. US Food and Drug Administration (FDA) Bovine Spongiform Encephalopathy (BSE) Testimony (2003). http://www.fda.gov/NewsEvents/Testimony/ucm161943.htm (Link: http://www.fda.gov/NewsEvents/Testimony/ucm161943.htm)
13. FDA Guidance. Guidance for Industry, Immediate Release Solid Oral Dosage Forms Scale-Up and Post-approval Changes: Chemistry, Manufacturing, and Controls, In Vitro Dissolution Testing, and In Vivo Bioequivalence Documentation (SUPAC-IR) (1995), U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER)
14. FDA Guidance. Guidance for Industry: The Sourcing and Processing of Gelatin to Reduce the Potential Risk Posed by Bovine Spongiform Encephalopathy (BSE) in FDA-Regulated Products for Human Use, Food and Drug Administration (1997). http://www.fda.gov/RegulatoryInformation/Guidances/ucm125182.htm (Link: http://www.fda.gov/RegulatoryInformation/Guidances/ucm125182.htm)
15. FDA Guidance. Guidance for Industry: Dissolution Testing of Immediate Release Solid Oral Dosage Forms (1997), U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER)
16. Greenspan L. Humidity fixed points of binary saturated aqueous solutions. J. Res. Natl. Bur. Stand. 81A (1977) 89-96
17. Grosswald, R.R., Anderson, J.B., Andrew, C.S., 1997. Method of manufacture of pharmaceutical cellulose capsules. US Patent No. 5,698,155, December.
18. Grosswald, R.R., Anderson, J.B., Andrew, C.S., 1998. Apparatus for the manufacture of pharmaceutical cellulose capsules. US Patent No. 5,750,157, May.
19. Grosswald, R.R., Anderson, J.B., Andrew, C.S., 1998. Method for the manufacture of pharmaceutical cellulose capsules. US Patent No. 5,656,036, May.
20. Kontny M.J., and Muslki C.A. Gelatin capsules as a function of relative humidity at room temperature. Int. J. Pharm. 54 (1989) 79-85
21. Ku M.S. Use of the biopharmaceutical classification system in early drug development. AAPS J. 10 (2008) 208-212
22. Ku M.S. Early formulation development approaches: Wyeth perspective. AAPS First-in-Human Formulation Strategy Symposia Presentation, AAPS Annual Meeting. Atlanta, GA (2008)
23. Liebowitz S.M., Vadino W.A., and Ambrosio T.J. Determination of hard gelatin capsule brittleness using a motorized compression test stand. Drug Dev. Ind. Pharm. 16 (1990) 995-1010
24. Matsuura, S., Tanjoh, M., 2003. Hard capsule formed of cellulose ether film with a specific content of methoxyl and hydroxypropoxyl groups. US Patent No. 6,649,180 B1, November.
25. Missaghi S., and Fassihi R. Evaluation and composition of physicomechanical characteristics of gelatin and hypromellose capsules. Drug Dev. Ind. Pharm. 32 (2006) 829-838
26. Murphy, H.W., 1950. Methyl cellulose capsules and process of manufacture. US Patent No. 2,526,683, October.
27. Nassar M.N., Nesarikar V.N., Lozano R., Parker W.L., Huang Y., Palaniswamy V., Xu W., and Khaselev N. Influence of formaldehyde impurity in the polysorbates 80 and PEG-300 on the stability of a parenteral formulation of BMS-204352: identification and control of the degradation product. Pharm. Dev. Tech. 9 (2004) 189-195
28. Ogura T., Furuya T., and Matsuura S. HPMC capsules-an alternative to gelatin. Pharm. Tech. Eur. 10 (1998) 32-42
29. ® Hypromellose Capsules Handbook (2005)
30. Rowe, R.C., Sheskey, P.S. Weller, P.J., 2003. Handbook of Pharmaceutical Excipients, 5th ed. Pharmaceutical Press (London, UK) and the American Pharmacists Association (Washington DC, USA).
31. Tuleu C., Khela M.K., Evans D.F., Jones B.E., Nagat S., and Basit A.W. A scintigraphic investigation of the disintegration behavior of capsules in fasting subjects: a comparison of hypromellose capsules containing carrageenan as a gelling agent and standard gelatin capsules. Eur. J. Pharm. Sci. 30 (2007) 251-255
32. US Pharmacopeia XXXII. US Pharmacopeial Convention, Rockville, MD, USP32/NF 27, USP<711> Dissolution (2009) pp 263-271
33. Yamamoto, T., Abe, K., Matsuura, S., 1993. Hard capsule for pharmaceutical drugs and method for producing the same. US Patent No. 5,264,223, November.
34. Yamamoto, T., Abe, K., Matsuura, S., 1995. Hard capsule for pharmaceutical drugs and method for producing the same. U.S. Patent No. 543,917, 11 July.
35. Yamamoto, T., Matsuura, S., Akai, K., 1998. Capsule shell. US Patent No. 5,756,123, 26 May.